KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Castle Biosciences (CSTL) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $986000.0 as the latest value for Q3 2021.

  • Quarterly Non-Current Deffered Revenue fell 13.51% to $986000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $986000.0 through Sep 2021, down 13.51% year-over-year, with the annual reading at $1.7 million for FY2020, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $986000.0 in Q3 2021 for Castle Biosciences, up from $963000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.7 million in Q4 2020 to a low of $44000.0 in Q4 2018.
  • Historically, Non-Current Deffered Revenue has averaged $697069.6 across 4 years, with a median of $952000.0 in 2020.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 1935.5% in 2020 and later decreased 13.51% in 2021.
  • Year by year, Non-Current Deffered Revenue stood at $44000.0 in 2018, then grew by 27.29% to $56006.0 in 2019, then skyrocketed by 2997.88% to $1.7 million in 2020, then tumbled by 43.17% to $986000.0 in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for CSTL at $986000.0 in Q3 2021, $963000.0 in Q2 2021, and $995000.0 in Q1 2021.